Physician profile
Tye B Young
NPI 1174635957
$4,926.97
in general payments reported to CMS, 2019-2025
45 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $154 · 2021: $196 · 2022: $518 · 2023: $900 · 2024: $1,264 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,370.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $836.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $478.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $373.42 | 2019-2025 | Farxiga, Airsupra |
| Abbvie INC. | $293.70 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Astellas Pharma US INC | $293.05 | 2019-2025 | Veozah |
| Amgen INC. | $252.09 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $250.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.22 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $226.80 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $179.65 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.82 | 2024-2025 | Caplyta |
| Antares Pharma, INC. | $104.18 | 2022-2025 | Xyosted |
| Si-Bone, INC. | $100.95 | 2022 | |
| Biogen, INC. | $91.33 | 2024-2025 | Skyclarys |
| Merck Sharp & Dohme LLC | $90.16 | 2019-2023 | Belsomra |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tye Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.